Linagliptin

Non Chimik:

8-[(3R)-3-aminopiperidin-1-yl]-7-(but-2-yn-1-yl)-3-methyl-1-[(4-methylquinazolin-2-yl)methyl]-3 ,7-dihydro-1H-purine-2,6-dyon

Kòd SMILES:

O=C(N1CC2=NC(C)=C3C=CC=CC3=N2)N(C)C4=C(N(CC#CC)C(N5C[C@H](N)CCC5)=N4)C1 =O

Kòd InChi:

InChI=1S/C25H28N8O2/c1-4-5-13-32-21-22(29-24(32)31-12-8-9-17(26)14-31)30(3)25(35) 33(23(21)34)15-20-27-16(2)18-10-6-7-11-19(18)28-20/h6-7,10-11,17H,8-9, 12-15,26H2,1-3H3/t17-/m1/s1

InChi kle:

LTXREWYXXSTFRX-QGZVFWFLSA-N

Mot:

Linagliptin, BI-1356, BI 1356, BI1356, 668270-12-0

Solibilite:Soluble nan DMSO

Depo:0 - 4 ° C pou kout tèm (jou a semèn), oswa -20 ° C pou tèm long (mwa).

Deskripsyon:

Linagliptin, ke yo rele tou BI-1356, se yon inibitè DPP-4 devlope pa Boehringer Ingelheim pou tretman dyabèt tip II. Linagliptin (yon fwa chak jou) te apwouve pa US FDA sou 2 me 2011 pou tretman dyabèt tip II. Li se Boehringer Ingelheim ak Lilly ki te commercialisés.

Sib: DPP-4